Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Phase II NCT06500884

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events — Recruiting • Phase II • Oncology • NCT06500884.

📅 01 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06500884
Sponsor
Janssen Research & Development, LLC
Start
2024-08-26
ClinicaliQ Trial Snapshot
  • A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events — Recruiting • Phase II • Oncology • NCT06500884.
  • The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to….
  • Sponsor: Janssen Research & Development, LLC.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.

Eligibility Snapshot
  • : * Multiple myeloma (MM) according to IMWG diagnostic criteria * Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb) * Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen * Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy * Be willing and able to adhere to the lifestyle restrictions specified in the protocol

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Oncology · 27 Mar 2026
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck…
View guideline →
Clinical Brief
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Oncology · BBC Health · 28 Mar 2026
Ultrasound service capacity is insufficient due to inadequate sonographer training, creating delays that compromise care for pregnant women and cancer patients requiring…
View brief →
Guideline
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment
Oncology · 07 May 2026
Zanidatamab is recommended by NICE as an option for HER2-positive advanced biliary tract cancer only after 1 or more prior lines of…
View guideline →
Guideline
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Oncology · 06 May 2026
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for…
View guideline →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →
Guideline
Prostate Cancer: Diagnosis and Management (NICE NG131)
Oncology · 27 Mar 2026
Offer PSA testing to men aged 50–69 years after informed discussion of benefits and harms; consider testing men aged 40–49 with family…
View guideline →